Inhalation Sciences signs CRO contract worth 30.5 KEUR with global pharmaceutical company
(Stockholm, 4 May, 2020) Inhalation Sciences (ISAB) has signed a CRO (Contract Research) order worth over 30 KEUR with a global pharmaceutical company. CEO Manoush Masarrat: “The demand for ISAB’s technology remains despite current challenges and restrictions related to Covid-19. With so much urgent research in the respiratory field ongoing right now, our in-house research is crucial. This order shows that the data our in vitro lung simulation tool DissolvIt[® ]deliver are, quite simply, leading.”The Contract Research will use ISAB’s in vitro simulation tool DissolvIt[®]. A leading in vitro